Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Jun 15;25(12):1867–1876. doi: 10.1091/mbc.E14-03-0839

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2014 Vaughan et al. This article is distributed by The American Society for Cell Biology under license from the author(s). Two months after publication it is available to the public under an Attribution–Noncommercial–Share Alike 3.0 Unported Creative Commons License (http://creativecommons.org/licenses/by-nc-sa/3.0).

“ASCB®,” “The American Society for Cell Biology®,” and “Molecular Biology of the Cell®” are registered trademarks of The American Society of Cell Biology.

PMC Copyright notice

FIGURE 5: — SPK601 inhibits PC-PLC, DAG production, and Rho and Cdc42 activation. (A) SPK601 (SPK) is as an effective inhibitor of PC-PLC in vitro as D609. Lipase activity of purified PC-PLC was assayed at the indicated concentrations of each inhibitor. (B) SPK601 suppresses DAG production around wounds. (B′) Quantification of wound DAG (p < 0.005). (C) SPK601 suppresses PA production around wounds. (C′) Quantification of wound PA (p < 0.005). (D) SPK601 suppresses Rho and Cdc42 activation around wounds. Intensity of Rho and Cdc42 zones from control and SPK601-treated cells was quantified at 60 s (Rho: control vs. SPK601, p < 0.005; Cdc42: control vs. SPK601, p < 0.005). Top and bottom whiskers represent maximum and minimum values, respectively. Scale bar, 20 μm.